Prognostic value of preoperative systemic immune-inflammation index/albumin for patients with hepatocellular carcinoma undergoing curative resection

Table 1 Patient demographics and baseline characteristics, n (%)

Characteristics	Total (n = 1653)
Sex
Female	247 (15)
Male	1406 (85)
Age, years
≤ 60	1185 (72)
> 60	468 (28)
Hepatitis B surface antigen
Negative	263 (16)
Positive	1390 (84)
Alpha-fetoprotein, ng/mL
< 400	1370 (83)
≥ 400	283 (17)
Platelets, 109/L
> 100	1,178 (71)
≤ 100	475 (29)
Neutrophil, 109/L
≤ 6.3	1577 (95)
> 6.3	76 (5)
Lymphocyte, 109/L
> 0.8	1547 (94)
≤ 0.8	106 (6)
Alanine transaminase, U/L
≤ 40	1199 (73)
> 40	454 (27)
Aspartate transaminase, U/L
≤ 40	966 (58)
> 40	687 (42)
Prothrombin time, second
≤ 13	1360 (82)
> 13	293 (18)
Total bilirubin, μmol/L
≤ 32.4	1630 (99)
> 32.4	23 (1)
Albumin, g/L
> 35	1572 (95)
≤ 35	81 (5)
Albumin-bilirubin grade
1	1279 (77)
2	374 (23)
Tumor diameter, cm
< 5	785 (47)
≥ 5	868 (53)
Number of tumors
Single	1389 (84)
Multiple	264 (16)
Barcelona Clinic Liver Cancer stage
0	152 (9)
A	1192 (72)
B	184 (11)
C	125 (8)
Hypertension
No	1397 (85)
Yes	256 (15)
Diabetes
No	1518 (92)
Yes	135 (8)
Cardiovascular disease
No	1624 (98)
Yes	29 (2)
Anatomical resection
No	1068 (65)
Yes	585 (35)
Major hepatectomy
No	1415 (86)
Yes	238 (14)
Transfusion
No	1557 (94)
Yes	96 (6)
Differentiation
I-II	898 (54)
III-IV	755 (46)
Microvascular invasion
No	1177 (71)
Yes	476 (29)
Cirrhosis
No	795 (48)
Yes	858 (52)
Portal vein tumor thrombus
No	1528 (92)
Yes	125 (8)
Systemic immune-inflammation index/albumin	6 (4, 10)
Systemic immune-inflammation index	271 (170, 447)
Neutrophil-to-lymphocyte ratio	2.10 (1.58, 2.93)
Platelet-to-lymphocyte ratio	88 (63, 125)

Median (interquartile range) for continuous variables.